Market news

Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.

Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...

Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

These are the stocks posting the largest moves midday.

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

Detailed price information for Revvity Inc (RVTY-N) from The Globe and Mail including charting and trades.

WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin

Revvity (RVTY) has agreed to acquire Human Cell Design (HCD), the company said Wednesday. Financ

Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...

Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo

Revvity (RVTY) has an average rating of overweight and mean price target of $123.50, according to an